Thalia Therapeutics Plc
Research Thalia Therapeutics Plc (THAT) on Bullrun: market cap GBX 561.79M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerTHAT
- ExchangeLSE
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyGBX
- Market capGBX 561.79M
- Financial periodFY2024
- RevenueGBP 7.28K
- Revenue growth272.9%
- Net income-GBP 1.06M
- Free cash flow-GBP 971.50K
- Gross margin100.0%
Valuation Snapshot
latest market cap is GBX 561.79M.
About Thalia Therapeutics Plc
Thalia Therapeutics Plc, a specialist pharmaceutical company, develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines in the United Kingdom. It develops Nuvec, a silica nanoparticle delivery system, which has an irregular surface structure that traps and protects siRNA/RNA/DNA; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene.
Frequently asked questions
What is Thalia Therapeutics Plc's market cap?
Thalia Therapeutics Plc's market capitalization is GBX 561.79M.
What does Thalia Therapeutics Plc do?
Thalia Therapeutics Plc, a specialist pharmaceutical company, develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines in the United Kingdom.